New insight for pulmonary fibrosis

23 September 2014

Research at Yale University has investigated a potential new treatment that could reverse the effect of pulmonary fibrosis. The disease affects the respiratory system and sees scars develop in the lungs, which can severely inhibit breathing.

The study, published in the journal European Molecular Biology Organization Molecular Medicine, used a microRNA mimic - miR-29 - which is delivered to lung tissue through the veins. In mouse models, the team found that miR-29 was able to block pulmonary fibrosis, and reverse the disease after several days.

Pulmonary fibrosis has an average survival of between three to five years after diagnosis, while there is no treatment that currently reverses the disease.

Dr Naftali Kaminski, a professor at Yale School of Medicine and section chief of pulmonary, critical care, and sleep medicine, said: "The mimic, when injected into the blood, goes to the lung and it has a sustained effect. We are very impressed that it can reverse fibrosis, not only prevent it." 

Dr Kaminski, who is also corresponding author of the study, said the next step will see the team evaluating miR-29 as a treatment option for idiopathic pulmonary fibrosis in humans.

Posted by Edward Bartel​


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)